Lyra Therapeutics, Inc. (LYRA)
OTCMKTS · Delayed Price · Currency is USD
0.6000
+0.0170 (2.92%)
At close: Jun 26, 2026
Lyra Therapeutics Earnings Call Transcripts
Fiscal Year 2025
-
Enlightened II phase III trial of LYR-210 in CRS met primary and key secondary endpoints, showing significant symptom and quality-of-life improvements with a strong safety profile. Plans are underway for FDA engagement and further studies in polyp patients.